Purdue's reformulated OxyContin gets second look by FDA panel
This article was originally published in Scrip
Executive Summary
The US FDA's outside advisors will take a second look at whether Purdue Pharma's proposed reformulation of OxyContin (oxycodone extended-release) should be approved for sale because it is less likely to be abused or misused.